Icon Plc $ICLR Shares Purchased by Nicholas Hoffman & Company LLC.

Nicholas Hoffman & Company LLC. raised its holdings in Icon Plc (NASDAQ:ICLR) by 65.6% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,954 shares of the medical research company’s stock after buying an additional 3,548 shares during the quarter. Nicholas Hoffman & Company LLC.’s holdings in Icon were worth $991,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Stephens Inc. AR boosted its position in shares of Icon by 102.0% in the first quarter. Stephens Inc. AR now owns 10,547 shares of the medical research company’s stock worth $1,167,000 after acquiring an additional 5,325 shares during the last quarter. Stephens Investment Management Group LLC increased its position in Icon by 10.3% during the first quarter. Stephens Investment Management Group LLC now owns 599,176 shares of the medical research company’s stock worth $66,305,000 after purchasing an additional 56,180 shares during the last quarter. Hudson Edge Investment Partners Inc. increased its position in Icon by 22.5% during the first quarter. Hudson Edge Investment Partners Inc. now owns 319,003 shares of the medical research company’s stock worth $35,301,000 after purchasing an additional 58,554 shares during the last quarter. USS Investment Management Ltd raised its stake in Icon by 4.4% during the first quarter. USS Investment Management Ltd now owns 14,015 shares of the medical research company’s stock worth $1,551,000 after purchasing an additional 587 shares during the period. Finally, Trinity Street Asset Management LLP boosted its holdings in shares of Icon by 12.7% in the 1st quarter. Trinity Street Asset Management LLP now owns 1,208,148 shares of the medical research company’s stock valued at $133,694,000 after purchasing an additional 135,720 shares during the last quarter. Institutional investors and hedge funds own 95.61% of the company’s stock.

Icon Price Performance

Icon stock opened at $168.72 on Wednesday. The firm has a fifty day moving average of $137.96 and a 200-day moving average of $137.39. Icon Plc has a 52-week low of $66.57 and a 52-week high of $211.00. The company has a quick ratio of 1.14, a current ratio of 1.14 and a debt-to-equity ratio of 0.31. The firm has a market capitalization of $12.92 billion, a P/E ratio of 30.02, a PEG ratio of 8.39 and a beta of 1.22.

Icon (NASDAQ:ICLR) last announced its quarterly earnings results on Tuesday, June 23rd. The medical research company reported $2.50 earnings per share for the quarter, topping analysts’ consensus estimates of $2.43 by $0.07. Icon had a net margin of 5.35% and a return on equity of 8.73%. The firm had revenue of $2.03 billion during the quarter, compared to analysts’ expectations of $1.98 billion. During the same period in the prior year, the company earned $3.43 EPS. The firm’s revenue was up 2.5% on a year-over-year basis. As a group, analysts predict that Icon Plc will post 9.43 EPS for the current year.

Analysts Set New Price Targets

Several analysts have recently issued reports on ICLR shares. Truist Financial raised shares of Icon from a “hold” rating to a “buy” rating and boosted their price objective for the company from $159.00 to $207.00 in a research note on Tuesday, June 30th. Piper Sandler cut Icon to a “neutral” rating in a report on Thursday, May 28th. Weiss Ratings downgraded Icon from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, May 29th. Robert W. Baird upped their price target on Icon from $168.00 to $186.00 and gave the stock an “outperform” rating in a research note on Thursday, June 25th. Finally, Mizuho raised their price objective on Icon from $180.00 to $190.00 and gave the stock an “outperform” rating in a report on Friday, June 26th. Nine investment analysts have rated the stock with a Buy rating, six have given a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, Icon presently has a consensus rating of “Hold” and an average price target of $173.19.

Icon Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.